Published in J Immunother on February 24, 2009
The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther (2009) 2.14
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses (2010) 1.30
Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther (2011) 1.26
Glioma virus therapies between bench and bedside. Neuro Oncol (2014) 0.95
Increasing the efficacy of oncolytic adenovirus vectors. Viruses (2010) 0.88
Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J Biomed Biotechnol (2010) 0.85
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Front Oncol (2014) 0.85
Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma. Neurosurgery (2012) 0.85
Reduced tumourigenicity of EG7 after RANTES gene transfer and the underlying mechanism. Arch Med Sci (2010) 0.84
New approaches to the development of adenoviral dendritic cell vaccines in melanoma. Curr Opin Investig Drugs (2010) 0.83
Co-transfection of dendritic cells with AFP and IL-2 genes enhances the induction of tumor antigen-specific antitumor immunity. Exp Ther Med (2012) 0.82
Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol (2011) 0.82
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol (2017) 0.79
Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. Biomedicines (2016) 0.78
Emerging role of Natural killer cells in oncolytic virotherapy. Immunotargets Ther (2015) 0.75
Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Cancer Immunol Immunother (2017) 0.75
Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4(+) T cells combined with agonist α-GITR mAb promotes durable CD8(+) T-cell-dependent antitumor immunity. Oncoimmunology (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol (1991) 10.58
Mouse and human dendritic cell subtypes. Nat Rev Immunol (2002) 10.01
Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature (1990) 7.15
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (1996) 5.97
IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev (2004) 4.78
Dendritic cell immunotherapy: mapping the way. Nat Med (2004) 4.28
Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med (1999) 4.20
Molecular cloning and functional characterization of a novel human CC chemokine receptor (CCR5) for RANTES, MIP-1beta, and MIP-1alpha. J Biol Chem (1996) 3.78
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3.64
A human T cell-specific molecule is a member of a new gene family. J Immunol (1988) 3.21
Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med (1992) 3.20
Understanding dendritic cell and T-lymphocyte traffic through the analysis of chemokine receptor expression. Immunol Rev (2000) 3.18
Retracted Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med (2000) 2.64
Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J Immunol (1995) 2.52
Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell (1989) 2.31
An antigenic peptide produced by peptide splicing in the proteasome. Science (2004) 2.20
Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol (2004) 2.14
A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. Hum Gene Ther (1998) 2.14
The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res (2002) 1.99
Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element. J Biol Chem (1991) 1.92
Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. J Leukoc Biol (1999) 1.84
Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol (2000) 1.72
C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins. J Immunol (1994) 1.66
Identification of RANTES receptors on human monocytic cells: competition for binding and desensitization by homologous chemotactic cytokines. J Exp Med (1993) 1.53
Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest (2004) 1.44
Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res (2004) 1.35
E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. Nat Biotechnol (2003) 1.34
The control of immunity and tolerance by dendritic cell. Pathol Biol (Paris) (2003) 1.33
Immune recognition of self in immunity against cancer. J Clin Invest (2004) 1.27
RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther (1996) 1.24
Intratumoral CC chemokine ligand 5 overexpression delays tumor growth and increases tumor cell infiltration. J Immunol (2004) 1.10
RANTES-induced chemokine cascade in dendritic cells. J Immunol (2001) 0.99
A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res (2003) 0.98
Tumor rejection and immune memory elicited by locally released LEC chemokine are associated with an impressive recruitment of APCs, lymphocytes, and granulocytes. J Immunol (2000) 0.98
Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol (2003) 0.98
Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res (2004) 0.98
Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest (2004) 0.95
Expression of inflammatory chemokines combined with local tumor destruction enhances tumor regression and long-term immunity. Cancer Res (2003) 0.90
Dendritic cells in vaccination therapies of human malignant disease. Blood Rev (2004) 0.89
Intratumoral injection of lipopolysaccharide causes regression of subcutaneously implanted mouse glioblastoma multiforme. Neurosurgery (2001) 0.86
Dendritic cells: limited potential in immunotherapy. Int J Biochem Cell Biol (2005) 0.86
TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model. Cancer Immunol Immunother (2008) 0.82
The effects of human recombinant MIP-1 alpha, MIP-1 beta, and RANTES on the chemotaxis and adhesion of T cell subsets. Adv Exp Med Biol (1993) 0.82
Characterization of a new spontaneously developed murine mammary adenocarcinoma in syngeneic BALB/c hosts. In Vitro Cell Dev Biol (1989) 0.81
Highly successful therapeutic vaccinations combining dendritic cells and tumor cells secreting granulocyte macrophage colony-stimulating factor. Cancer Res (2004) 0.81
Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat Biotechnol (2004) 2.41
c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma. Hepatology (2014) 2.04
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood (2002) 1.89
SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J Clin Invest (2005) 1.75
A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med (2008) 1.65
Control of B cell development by the histone H2A deubiquitinase MYSM1. Immunity (2011) 1.63
Mucosal and systemic anti-HIV immunity controlled by A20 in mouse dendritic cells. J Clin Invest (2011) 1.54
CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther (2005) 1.51
Stable knockdown of estrogen receptor alpha by vector-based RNA interference suppresses proliferation and enhances apoptosis in breast cancer cells. Cancer Biol Ther (2006) 1.44
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Mol Ther (2011) 1.32
Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res (2002) 1.23
HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. Gastroenterology (2011) 1.22
An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. PLoS Med (2006) 1.15
Twist-2 controls myeloid lineage development and function. PLoS Biol (2008) 1.10
The endoplasmic reticulum chaperone protein GRP94 is required for maintaining hematopoietic stem cell interactions with the adult bone marrow niche. PLoS One (2011) 1.07
Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells. Cancer Res (2002) 1.05
CCL5 as an adjuvant for cancer immunotherapy. Expert Opin Biol Ther (2010) 1.05
Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Mol Ther (2004) 1.03
The control of hematopoietic stem cell maintenance, self-renewal, and differentiation by Mysm1-mediated epigenetic regulation. Blood (2013) 0.99
A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. Cancer Res (2003) 0.98
Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res (2004) 0.98
IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity. J Immunol (2010) 0.97
Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Mol Ther (2009) 0.95
Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res (2003) 0.95
Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res (2003) 0.95
Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells (2009) 0.94
Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology (2007) 0.94
Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. J Immunother (2013) 0.94
A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells. Mol Ther (2010) 0.92
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting. Immunol Rev (2008) 0.92
Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther (2006) 0.92
Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother (2003) 0.91
Intrabody and intrakine strategies for molecular therapy. Mol Ther (2003) 0.91
HER2-mediated upregulation of MMP-1 is involved in gastric cancer cell invasion. Arch Biochem Biophys (2010) 0.90
Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res (2007) 0.90
Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods (2003) 0.89
Lentiviral transduction of human dendritic cells. Methods Mol Biol (2004) 0.89
Human suppressor of cytokine signaling 1 controls immunostimulatory activity of monocyte-derived dendritic cells. Cancer Res (2009) 0.89
Identification of a MHC class-II restricted epitope in carcinoembryonic antigen. Cancer Immunol Immunother (2003) 0.88
Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J Biol Chem (2004) 0.85
A caspase-6 and anti-human epidermal growth factor receptor-2 (HER2) antibody chimeric molecule suppresses the growth of HER2-overexpressing tumors. J Immunol (2004) 0.85
Epigenetic control of natural killer cell maturation by histone H2A deubiquitinase, MYSM1. Proc Natl Acad Sci U S A (2013) 0.84
Enhanced intracellular stability of sFv-Fc fusion intrabodies. Methods (2004) 0.84
Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen. Clin Cancer Res (2003) 0.83
Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treat Rev (2012) 0.83
Dendritic cell-based tumor vaccines and antigen presentation attenuators. Mol Ther (2006) 0.82
Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies. J Immunol Methods (2002) 0.82
A super TLR agonist to improve efficacy of dendritic cell vaccine in induction of anti-HCV immunity. PLoS One (2012) 0.80
Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis. FASEB J (2003) 0.80
A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity. Vaccine (2009) 0.80
HER2-targeting recombinant protein with truncated pseudomonas exotoxin A translocation domain efficiently kills breast cancer cells. Cancer Biol Ther (2008) 0.80
Anti-tumor immune responses following neoadjuvant immunotherapy with a recombinant adenovirus expressing HSP72 to rodent tumors. Cancer Immunol Immunother (2005) 0.80
Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence. Clin Cancer Res (2010) 0.79
[Abscopal effect on metastatic tumor induced by oncolytic virus of H101 combining with local heating]. Ai Zheng (2006) 0.78
Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. Cancer Lett (2009) 0.78
A20 controls macrophage to elicit potent cytotoxic CD4(+) T cell response. PLoS One (2012) 0.78
SOCS1 silencing can break high-dose dendritic cell immunotherapy-induced immune tolerance. Mol Med Rep (2011) 0.78
The effect of direct translocation across endosomes on the cytotoxicity of the recombinant protein e23sFv-Fdt-casp6 to HER2 positive gastric cancer cells. Biomaterials (2011) 0.77
Enhanced generation of myeloid lineages in hematopoietic differentiation from embryonic stem cells by silencing transcriptional repressor Twist-2. Cloning Stem Cells (2009) 0.77
SOCS1 downregulation in dendritic cells promotes memory T-cell responses. Vaccine (2007) 0.77
Suppressor of cytokine signaling 1 inhibition strategy to enhance anti-HIV vaccination. Expert Rev Vaccines (2006) 0.76
Inhibition of antigen-presentation attenuators to augment vaccines. Curr Opin Mol Ther (2006) 0.76
Cloning of apoB intrabodies: specific knockdown of apoB in HepG2 cells. Biochem Biophys Res Commun (2008) 0.76